Gilead Sciences, Inc. and Merck, known as MSD outside the United States and Canada, have recently revealed compelling phase 2 data from a clinical trial involving their investigational combination therapy. The study evaluated the efficacy of a once-weekly oral regimen of islatravir (an investigational nucleoside reverse transcriptase translocation inhibitor) and lenacapavir (a first-in-class capsid inhibitor) in maintaining viral suppression among individuals. Concurrently, Merck Animal Health, a division of Merck & Co. Inc. announced a positive opinion from the European Medicines Agency’s Committee for Veterinary Medicinal Products regarding an injectable formulation of BRAVECTO (fluralaner) for dogs. Additionally, Merck announced the discontinuation of the Phase 3 KEYLYNK-008 trial, combining KEYTRUDA (pembrolizumab) and LYNPARZA (olaparib), for the treatment of metastatic squamous non-small cell lung cancer (NSCLC), based on the recommendation of an independent Data Monitoring Committee (DMC).
Gilead and Merck’s Preliminary Study Shows Promise for Islatravir and Lenacapavir Combination TherapyGilead Sciences and Merck have announced favorable results from a Phase 2 clinical study investigating the potential of an investigational combination therapy comprising islatravir and lenacapavir. The trial aimed to evaluate the efficacy of this once-weekly oral regimen in maintaining viral suppression. Islatravir is a nucleoside reverse transcriptase translocation inhibitor that hinders the replication of HIV-1 virus, while lenacapavir is a pioneering capsid inhibitor that blocks viral replication at an early stage. The encouraging findings indicate that the combination regimen effectively sustained viral suppression for up to 24 weeks. This success holds the promise of reduced dosing and enhanced treatment convenience for patients.
Merck Animal Health’s BRAVECTO Receives Positive Opinion from European Medicines AgencyMerck Animal Health, a subsidiary of Merck & Co. has achieved a significant milestone with the European Medicines Agency’s Committee for Veterinary Medicinal Products issuing a favorable opinion for BRAVECTO (fluralaner) 150mg/ml powder and solvent suspension for injection for use in dogs. BRAVECTO is an advanced treatment aimed at persistently killing fleas and ticks. The positive opinion from the CVMP further paves the way towards regulatory approval for this innovative product in the European market, potentially bolstering Merck Animal Health’s position in the lucrative veterinary pharmaceutical industry.
Merck’s KEYLYNK-008 Trial Halted Due to FutilityMerck has made the decision to terminate its Phase 3 KEYLYNK-008 trial weighing the combination therapy of KEYTRUDA and LYNPARZA for the treatment of metastatic squamous non-small cell lung cancer (NSCLC). KEYTRUDA is an anti-PD-1 therapy developed by Merck, while LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor. The discontinuation of the study follows the recommendation of an independent Data Monitoring Committee (DMC), based on their review of the trial data. Although the cessation of the KEYLYNK-008 trial is disappointing for Merck, the company remains committed to exploring other groundbreaking therapies that can benefit patients with NSCLC.
Implications for the Companies:The positive outcomes from the investigational combination of islatravir and lenacapavir therapy hold great promise for Gilead Sciences and Merck. If further trials continue to demonstrate the efficacy and safety of this oral regimen, it could potentially revolutionize the field of HIV treatment. Gilead and Merck may also benefit from the expected approval of BRAVECTO for dogs, as this injectable formulation offers a novel approach to combatting fleas and ticks. Furthermore, while the discontinuation of the KEYLYNK-008 trial is a disappointment for Merck, it underscores the company’s commitment to robust clinical evaluation and ensuring patient safety.
Comments